How much does evantuzumab cost? Will its market pricing fluctuate?

Amivantamab (Amivantamab) is a bispecific antibody targeting EGFR and MET. It is mainly used to treat patients with non-small cell lung cancer (NSCLC), especially those with EGFR Patients with exon 20 insertion mutations. Since the drug has just been launched in China and the market supply is not yet stable, it may be difficult for domestic patients to purchase it directly. Specific drug purchase channels and supply conditions still need to be consulted with relevant medical institutions or pharmacies.

At present, evantumumab has been launched in Hong Kong, China, and the original research version is available. It is understood that the market price of the drug in Hong Kong is about NT$10,000. Compared with other targeted drugs that have been marketed, the price of evantumumab is relatively high, but due to its precise therapeutic effect on specific gene mutations, it is still an important treatment option for some patients with advanced lung cancer.

Since the market pricing of new drugs in the early stages of launch is usually affected by factors such as production costs, market demand, medical insurance policies and competition, the price of evantumumab may fluctuate in the future. If the drug is later included in domestic medical insurance, patients' drug purchase burden may be reduced. In addition, as market supply stabilizes and international market prices adjust, its pricing strategy may change.

For domestic patients, if it is difficult to obtain the drug in the short term, they can pay attention to its supply situation in other countries or regions, such as the market price in the United States, Europe or other Asian countries, and consult professional medical institutions or cross-border drug purchase platforms to obtain the latest drug purchase information. At the same time, the availability and price of the drug in the country may improve over time, and patients should pay close attention to the latest developments from official channels.

Reference materials:https://www.rybrevant.com/